Prosecution Insights
Prosecution Insights
69 pending office actions • 47 clients • 64 examiners • 40 art units • 0 of 69 (0%) have an AI response strategy ready • 69 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 31 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 31 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (1%) |
| §103 only | 40 (58%) |
| §102 only | 6 (9%) |
| §112 only | 6 (9%) |
| Double-patenting only | 6 (9%) |
| No statute on record | 10 (14%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DOAN, HY KHANH | 2 | 70.4% | +34.8% |
| STEADMAN, DAVID J | 2 | 57.6% | +29.6% |
| GAO, ASHLEY HARTMAN | 2 | 58.1% | +41.7% |
| SCHWECHTER, BRANDON ROSS | 2 | — | — |
| PATTERSON, SARAH COOPER | 2 | 58.8% | +57.9% |
| SONG, JIANFENG | 1 | 56.0% | +33.5% |
| TRAN, CHRISTINA L | 1 | 48.1% | +43.5% |
| MI, QIUWEN | 1 | 68.3% | +49.7% |
| ANTHOPOLOS, PETER | 1 | 57.1% | +59.0% |
| CHOWDHURY, IQBAL HOSSAIN | 1 | 73.7% | +57.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17756203 | METHODS AND SYSTEMS FOR MANAGING DISTRIBUTION AND TREATMENT OF A FOOD ALLERGY ORAL IMMUNOTHERAPY DRUG | COLEMAN, CHARLES P. | 43d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17128599 | BISPECIFIC SIGNALING AGENTS AND USES THEREOF | GAO, ASHLEY HARTMAN | 33d |
| 19190263 | AQUEOUS OPHTHALMIC SOLUTIONS OF PHENTOLAMINE AND MEDICAL USES THEREOF | SONG, JIANFENG | — |
| 17612845 | ASYMMETRIC SIRNA INHIBITING EXPRESSION OF PD-1 | TRAN, CHRISTINA L | — |
| 18837449 | USE OF BLINK REFLEX FOR ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD) RESPONSE MONITORING AND/OR TREATMENT SELECTION | DOAN, HY KHANH | — |
| 18837441 | USE OF BLINK REFLEX FOR HEADACHE RESPONSE MONITORING AND/OR TREATMENT SELECTION | DOAN, HY KHANH | — |
| 18766245 | WILLOW EXTRACT AND ITS USE IN TREATING A VIRAL INFECTION, ALLERGIC REACTION, AND OTHER MEDICAL CONDITIONS | MI, QIUWEN | — |
| 18726667 | STABLE FORMULATIONS OF LIPID-ENCAPSULATED RNA | ANTHOPOLOS, PETER | — |
| 18722982 | ENZYMES, CELLS, AND METHODS FOR PRODUCING LACTONES | CHOWDHURY, IQBAL HOSSAIN | — |
| Art Unit | Apps |
|---|---|
| 1674 | 5 |
| 1629 | 4 |
| 1613 | 3 |
| 1637 | 3 |
| 1656 | 3 |
| 1678 | 3 |
| 1699 | 3 |
| 1622 | 3 |
| 1624 | 3 |
| 1675 | 3 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 19190263 | AQUEOUS OPHTHALMIC SOLUTIONS OF PHENTOLAMINE AND MEDICAL USES THEREOF | Opus Genetics, Inc. | SONG, JIANFENG | 1613 | §102 | Non-Final OA | — | Pending | Apr 25, 2025 |
| 17612845 | ASYMMETRIC SIRNA INHIBITING EXPRESSION OF PD-1 | Olix Pharmaceuticals, Inc. | TRAN, CHRISTINA L | 1637 | §103 | Non-Final OA | — | Pending | Apr 03, 2025 |
| 18837449 | USE OF BLINK REFLEX FOR ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD) RESPONSE MONITORING AND/OR TREATMENT SELECTION | Blinktbi, Inc. | DOAN, HY KHANH | §103 | Non-Final OA | — | Pending | Aug 09, 2024 | |
| 18837441 | USE OF BLINK REFLEX FOR HEADACHE RESPONSE MONITORING AND/OR TREATMENT SELECTION | Blinktbi, Inc. | DOAN, HY KHANH | §103 | Non-Final OA | — | Pending | Aug 09, 2024 | |
| 18766245 | WILLOW EXTRACT AND ITS USE IN TREATING A VIRAL INFECTION, ALLERGIC REACTION, AND OTHER MEDICAL CONDITIONS | Shireen Nature Company For General Trading, Ltd. | MI, QIUWEN | 1655 | §103 | Non-Final OA | — | Pending | Jul 08, 2024 |
| 18726667 | STABLE FORMULATIONS OF LIPID-ENCAPSULATED RNA | Greenlight Biosciences, Inc. | ANTHOPOLOS, PETER | 1611 | §103 | Non-Final OA | — | Pending | Jul 03, 2024 |
| 18722982 | ENZYMES, CELLS, AND METHODS FOR PRODUCING LACTONES | Manus Bio Inc. | CHOWDHURY, IQBAL HOSSAIN | 1656 | §112 | Non-Final OA | — | Pending | Jun 21, 2024 |
| 18719423 | SEQUENCES AND METHODS FOR PRODUCTION OF RECOMBINANT BIOLOGICAL MOLECULES IN VESICLES | Fujifilm Diosynth Biotechnologies UK Limited | STEADMAN, DAVID J | 1656 | §102 | Non-Final OA | — | Pending | Jun 13, 2024 |
| 18663500 | HYDROGEN-ENHANCED TRANSDERMAL SYSTEM | H2 Universe, LLC | STEVENS, MARK V | 1613 | §103 | Non-Final OA | — | Pending | May 14, 2024 |
| 18625774 | SIRP1a TARGETED CHIMERIC PROTEINS AND USES THEREOF | Orionis Biosciences BV | GAO, ASHLEY HARTMAN | 1678 | §112 | Final Rejection | — | Pending | Apr 03, 2024 |
| 18416004 | METHODS AND COMPOSITIONS TO INHIBIT TOLERANCE TO OPIOIDS | Sen-Jam Pharmaceutical Inc. | GULLEDGE, BRIAN M | 1699 | DP | Non-Final OA | — | Pending | Jan 18, 2024 |
| 18572316 | 4-ETHYNYL-3-HYDROXY-TETRAHYDROFURANYL-ADENINE PHOSPHORAMIDATES AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | Rome Therapeutics, Inc. | BRANDSEN, BENJAMIN MICHAEL | 1699 | §103 | Non-Final OA | — | Pending | Dec 20, 2023 |
| 18541560 | Methods and Compositions to Inhibit Symptoms Associated with Viral Upper Respiratory Tract Infections | Sen-Jam Pharmaceutical Inc. | HOWELL, THEODORE R | 1628 | DP | Non-Final OA | — | Pending | Dec 15, 2023 |
| 18538201 | DUAL-WAVELENGTH LASER SYSTEMS AND MATERIAL PROCESSING UTILIZING SUCH SYSTEMS | Panasonic Intellectual Property Management Co., Ltd. | KIRKWOOD, SPENCER HAMMETT | 3761 | §103 | Non-Final OA | 46d overdue | Pending | Dec 13, 2023 |
| 18563277 | ALKALINE PHOSPHATASE-BASED TREATMENTS OF CELIAC DISEASE | Theriva Biologics, Inc. | DAVIS, RUTH A | 1699 | §103 | Final Rejection | 22d overdue | Pending | Nov 21, 2023 |
| 18516381 | HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE | Halda Therapeutics Opco, Inc. | ELENISTE, PIERRE PAUL | 1622 | §103 | Non-Final OA | — | Pending | Nov 21, 2023 |
| 18561644 | METHODS OF TREATING MEDICAL CONDITIONS AND INHIBITING LINE1 REVERSE TRANSCRIPTASE USING A SUBSTITUTED 4-FLUORO-2,5-DIHYDROFURANYL PHOSPHONIC ACID OR RELATED COMPOUND | Rome Therapeutics, Inc. | KRISHNAN, GANAPATHY | 1693 | §103 | Non-Final OA | 28d | Pending | Nov 16, 2023 |
| 18560260 | ENZYMES, HOST CELLS, AND METHODS FOR PRODUCTION OF ROTUNDONE AND OTHER TERPENOIDS | Manus Bio Inc. | GORDON, MELENIE LEE | 1651 | §102 | Non-Final OA | 23d | Pending | Nov 10, 2023 |
| 18288435 | METHODS AND COMPOSITIONS FOR TREATMENT OF DIABETIC RETINOPATHY AND RELATED CONDITIONS | Opus Genetics, Inc. | DEKARSKE, MADELINE MCGUIRE | 1622 | Other | Non-Final OA | 44d overdue | Pending | Oct 26, 2023 |
| 18556599 | METHODS AND COMPOSITIONS FOR TREATING MYDRIASIS, GLAUCOMA, AND OTHER OCULAR CONDITIONS | Opus Genetics, Inc. | DAHLIN, HEATHER RAQUEL | 1629 | DP | Non-Final OA | — | Pending | Oct 20, 2023 |
| 18553954 | BUILDING MATERIALS | Dmat S.r.l. | GREEN, ANTHONY J | 1731 | §103 | Final Rejection | 84d overdue | Pending | Oct 04, 2023 |
| 18367631 | SALTS AND ESTERS OF APX3330 AND THERAPEUTIC USES THEREOF | Opus Genetics, Inc. | ROMERO, KRISTEN WANG | 1624 | Other | Non-Final OA | 18d overdue | Pending | Sep 13, 2023 |
| 18280712 | CHIMERIC PROTEINS IN AUTOIMMUNITY | Shattuck Labs, Inc. | NICKOL, GARY B | 1643 | §103 | Non-Final OA | 28d | Pending | Sep 07, 2023 |
| 18549033 | USP30 INHIBITORS AND USES THEREOF | Vincere Biosciences, Inc. | MCANANY, JOHN D | 1625 | DP | Non-Final OA | — | Pending | Sep 05, 2023 |
| 18275880 | ARYLTHIOETHER ACETAMIDE AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | X-Biotix Therapeutics, Inc. | VAJDA, KRISTIN ANN | 1622 | §102 | Non-Final OA | 16d | Pending | Aug 04, 2023 |
| 18272428 | MATERIALS AND METHODS FOR DIAGNOSIS | Qsm Diagnostics, Inc. | KAUR, GURPREET | 1759 | §103 | Final Rejection | — | Pending | Jul 14, 2023 |
| 18269036 | METHODS AND COMPOSITIONS RELATED TO BCL2 AND BIM HETERODIMER ANTIBODIES | Eutropics Pharmaceuticals, Inc. | MACFARLANE, STACEY NEE | 1675 | §112 | Non-Final OA | — | Pending | Jun 22, 2023 |
| 18257767 | TRANSGENIC ANIMALS AND PREPARATIONS THEREOF FOR BIOREMEDIATION | Entozyme Pty Ltd. | STEADMAN, DAVID J | 1656 | §103 | Non-Final OA | — | Pending | Jun 15, 2023 |
| 18334909 | COMPOSITIONS FOR USE IN THE TREATMENT OF CHD2 HAPLOINSUFFICIENCY AND METHODS OF IDENTIFYING SAME | Yeda Research And Development Co. Ltd. | LIPPOLIS, ALEXANDRA ROSE | 1637 | DP | Non-Final OA | — | Pending | Jun 14, 2023 |
| 17996343 | STABLE DIGLYCERIDE EMULSIONS AND METHODS FOR TREATING ORGAN INJURY | The Trustees of Columbia University in the City of New York | CORNET, JEAN P | 1628 | Other | Non-Final OA | 13d | Pending | Jun 13, 2023 |
| 18265508 | MANUFACTURE OF GRANULOCYTE MACROPHAGE-COLONY STIMULATING FACTOR | Partner Therapeutics, Inc. | SCHWECHTER, BRANDON ROSS | 1674 | §102 | Non-Final OA | — | Pending | Jun 06, 2023 |
| 18265048 | METHODS OF TREATING CANCER USING TIGIT-AND LIGHT-BASED CHIMERIC PROTEINS | Shattuck Labs, Inc. | ABBAS, SYED JARAR | 1674 | Other | Non-Final OA | — | Pending | Jun 02, 2023 |
| 18038067 | GLYCOSIDE PRODUCT BIOSYNTHESIS AND RECOVERY | Manus Bio Inc. | ARIANI, KADE | 1651 | §103 | Non-Final OA | 71d | Pending | May 22, 2023 |
| 18034120 | GENOME-MODIFIED BACTERIAL STRAINS FOR LARGE SCALE BIOPROCESSES | Manus Bio Inc. | HAUK TEODORO, PRICILA NMN | 1645 | §103 | Non-Final OA | 3d overdue | Pending | Apr 27, 2023 |
| 18030153 | A PHARMACEUTICAL FORMULATION FOR PRESSURISED METERED DOSE INHALER | Chiesi Farmaceutici S.p.A. | BASQUILL, SEAN M | 1614 | Other | Final Rejection | — | Pending | Apr 04, 2023 |
| 18029954 | CLEC9A antibodies | The University of Queensland | ROONEY, NORA MAUREEN | 1641 | §112 | Non-Final OA | — | Pending | Apr 03, 2023 |
| 18187943 | SILICA FIBER COMPOSITIONS AND METHODS OF USE | American Nano, LLC | BECKHARDT, LYNDSEY MARIE | 1613 | §103 | Non-Final OA | 15d | Pending | Mar 22, 2023 |
| 18179178 | METHODS FOR TREATING CHRONIC RHINOSINUSITIS | Optinose, Inc. | JONES, AISLINN MOIRA | 3785 | §103 | Final Rejection | — | Pending | Mar 06, 2023 |
| 18023912 | MICROBIAL PRODUCTION OF ARTEMISINIC ACID AND DERIVATIVES | Manus Bio Inc. | WHITE, ASHLEY TAYLOR | 1653 | §103 | Non-Final OA | 72d | Pending | Feb 28, 2023 |
| 18020734 | METHOD FOR THE TREATMENT OF WWOX ASSOCIATED DISEASES | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. | BATES, KEENAN ALEXANDER | 1631 | §103 | Final Rejection | — | Pending | Feb 10, 2023 |
| 18163026 | TARGETED MODIFIED IL-1 FAMILY MEMBERS | Centre Hospitalier Regional Universitaire De Montpellier | SCHWECHTER, BRANDON ROSS | 1674 | §112 | Non-Final OA | — | Pending | Feb 01, 2023 |
| 18017927 | SAMPLE HANDLING FOR DIAGNOSTICS | Qsm Diagnostics, Inc. | SUN, CAITLYN MINGYUN | 1795 | §103 | Final Rejection | 70d | Pending | Jan 25, 2023 |
| 18010266 | USE OF BLUE LIGHT FOR INDUCTION OF ANGIOGENESIS | Angio Gbr | LUKJAN, SEBASTIAN X | 3792 | §103 | Non-Final OA | 7d | Pending | Dec 14, 2022 |
| 18072385 | OPHTHALMIC DRUG DELIVERY DEVICE | Contactrx LLC | RASSAVONG, ERIC | 3781 | §103 | Non-Final OA | 10d overdue | Pending | Nov 30, 2022 |
| 17989905 | CELL COMPOSITIONS COMPRISING ANTIGEN-SPECIFIC T CELLS FOR ADOPTIVE THERAPY | Neximmune, Inc. | BELYAVSKYI, MICHAIL A | 1644 | Other | Final Rejection | 10d overdue | Pending | Nov 18, 2022 |
| 17923294 | FRUIT FLY CONTROL | Macquarie University | RAMACHANDRAN, UMAMAHESWARI | 1627 | §103 | Final Rejection | 60d overdue | Pending | Nov 04, 2022 |
| 18047506 | BENZODIAZEPINE DERIVATIVES AS GABA A GAMMA1 PAM | Hoffmann-La Roche, Inc. | SAMSELL, RILLA MARIE | 1624 | Other | Final Rejection | 26d | Pending | Oct 18, 2022 |
| 17939634 | METHODS OF REVERSING CACHEXIA AND PROLONGING SURVIVAL COMPRISING ADMINISTERING A GDF15 MODULATOR AND AN ANTI-CANCER AGENT | Aveo Pharmaceuticals, Inc. | FORD, VANESSA L | 1674 | §112 | Final Rejection | 30d | Pending | Sep 07, 2022 |
| 17801067 | PRESSURISED METERED DOSE INHALERS COMPRISING A BUFFERED PHARMACEUTICAL FORMULATION | Chiesi Farmaceutici S.p.A. | JANG, JAEICK | 3785 | §103 | Final Rejection | 12d | Pending | Aug 19, 2022 |
| 17786161 | COMPOUNDS MODULATING PROTEIN RECRUITMENT AND/OR DEGRADATION | Orionis Biosciences, Inc. | YOUNGBLOOD, WILLIAM JUSTIN | 1629 | §102 | Final Rejection | — | Pending | Jun 16, 2022 |
| 17785676 | DETECTION OF NOVEL DEGRADATION-RELATED INTERACTIONS | Orionis Biosciences, Inc. | PAK, MICHAEL D | 1674 | §103 | Final Rejection | — | Pending | Jun 15, 2022 |
| 17785359 | DETECTION OF MOLECULAR INTERACTIONS | Orionis Biosciences, Inc. | GOMEZ RODRIGUEZ, JULIO WASHINGTON | 1637 | §103 | Non-Final OA | — | Pending | Jun 14, 2022 |
| 17756203 | METHODS AND SYSTEMS FOR MANAGING DISTRIBUTION AND TREATMENT OF A FOOD ALLERGY ORAL IMMUNOTHERAPY DRUG | Société des Produits Nestlé S.A. | COLEMAN, CHARLES P. | 3683 | §101 | Non-Final OA | 43d overdue | Pending | May 19, 2022 |
| 17745307 | TARGETED CHIMERIC PROTEINS AND USES THEREOF | UNIVERSITEIT GENT | PATTERSON, SARAH COOPER | 1675 | DP | Final Rejection | — | Pending | May 16, 2022 |
| 17725692 | ALKALINE PHOSPHATASE AGENTS FOR TREATMENT OF NEURODEVELOPMENTAL DISORDERS | Theriva Biologics, Inc. | IANNUZO, NATALIE NMN | 1653 | §103 | Non-Final OA | — | Pending | Apr 21, 2022 |
| 17770747 | AGENT DELIVERY SYSTEMS, DEVICES, AND METHODS | Invictus Therapeutics, LLC | KOO, BENJAMIN K | 3783 | §103 | Non-Final OA | — | Pending | Apr 21, 2022 |
| 17690680 | Methods and Compositions to Inhibit Symptoms Associated with Opioid Withdrawal | Sen-Jam Pharmaceutical LLC | NEAGU, IRINA | 1629 | §103 | Final Rejection | 39d | Pending | Mar 09, 2022 |
| 17630258 | INSULIN ANALOGUES WITH GLUCOSE REGULATED CONFORMATIONAL SWITCH | Thermalin Inc. | BRADLEY, CHRISTINA | 1654 | §103 | Final Rejection | 4d overdue | Pending | Jan 26, 2022 |
| 17626932 | INTESTINAL ALKALINE PHOSPHATASE-BASED TREATMENTS OF METABOLIC DISORDERS | Theriva Biologics, Inc. | DURYEE, ALEXANDER MARSH | 1657 | §103 | Non-Final OA | — | Pending | Jan 13, 2022 |
| 17442772 | FMS-LIKE TYROSINE KINASE 3 LIGAND (FLT3L)-BASED CHIMERIC PROTEINS | UNIVERSITEIT GENT | PATTERSON, SARAH COOPER | 1675 | §103 | Non-Final OA | — | Pending | Sep 24, 2021 |
| 17412070 | NON PEPTIDIC HETEROBIVALENT MOLECULES FOR TREATING INFLAMMATORY DISEASES | Glaxosmithkline Intellectual Property Development Limited | SCHMITT, MICHAEL J | 1629 | Other | Final Rejection | 29d | Pending | Aug 25, 2021 |
| 17415248 | PARTICLE BASED SMALL MOLECULE-PROTEIN COMPLEX TRAP | Orionis Biosciences BV | RAMADAN, OMAR | 1678 | §103 | Final Rejection | 26d | Pending | Jun 17, 2021 |
| 17415216 | FLUORINATED BILE ACIDS | The University Of Southampton | MOORE, SUSANNA | 1624 | §103 | Non-Final OA | — | Pending | Jun 17, 2021 |
| 17348902 | PROTEIN-CONTAINING ADHESIVES, AND MANUFACTURE AND USE THEREOF | Evertree | WU, ANDREA | 1763 | §103 | Final Rejection | — | Pending | Jun 16, 2021 |
| 17172387 | LARAZOTIDE COMPOSITIONS AND METHODS FOR TREATING CANCER | Institut Gustave Roussy | FISCHER, JOSEPH | 1658 | Other | Non-Final OA | 4d overdue | Pending | Feb 10, 2021 |
| 17128599 | BISPECIFIC SIGNALING AGENTS AND USES THEREOF | UNIVERSITEIT GENT | GAO, ASHLEY HARTMAN | 1678 | §103 | Final Rejection | 33d | Pending | Dec 21, 2020 |
| 17252447 | METHODS OF MAKING ALKALINE PHOSPHATASE AGENTS | Theriva Biologics, Inc. | RAMIREZ, DELIA M | 1652 | §103 | Non-Final OA | — | Pending | Dec 15, 2020 |
| 16461680 | USE OF VIRAL VECTORS IN THE TREATMENT OF RETINOBLASTOMA | Hospital Sant Joan De Deu | HILL, KEVIN KAI | 1638 | §103 | Final Rejection | 86d overdue | Pending | May 16, 2019 |
| 15678823 | SIRNA STRUCTURE FOR MINIMIZING OFF-TARGET EFFECTS AND RELAXING SATURATION OF RNAI MACHINERY AND THE USE THEREOF | Dong Ki Lee | SHIN, DANA H | 1635 | Other | Final Rejection | 88d overdue | Pending | Aug 16, 2017 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial